Basic Information
Modis Therapeutics is a biopharmaceutical company dedicated to developing disease-modifying therapies for rare genetic disorders to address unmet medical needs. We were founded in 2016 through collaboration with academic experts in mitochondrial biology. Our lead program (MT1621) is currently in clinical development for Thymidine Kinase 2 Deficiency (TK2d), an inherited mitochondrial disease.
Modis Therapeutics, Inc.
California,United States of America
15~50 people
January 01, 2016
info@modistx.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios